Navigation Links
Hagens Berman Appointed Co-Lead Counsel in Case Against Schering-Plough and Merck
Date:6/10/2008

Lawsuit claims manufacturers misled consumers about the use of Zetia and

Vytorin.

SEATTLE, June 10 /PRNewswire/ -- Last week the U.S. District Court in New Jersey appointed Hagens Berman, along with four other firms, co-counsel in a case against Schering-Plough (NYSE: SGP) and Merck (NYSE: MRK) which claims the companies knowingly misled consumers on the use of popular prescription drugs Zetia and Vytorin.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080317/AQM144LOGO)

Judge Dennis Cavanaugh approved and ordered an organizational structure consisting of five law firms to comprise a Plaintiffs Steering Committee which is responsible for coordinating plaintiffs during pretrial proceedings and more.

The order states that within one week defendants and plaintiffs are to submit a proposed schedule regarding the filing of a consolidated amended complaint.

The lawsuit, filed on Jan. 17, 2008, claims Schering-Plough and Merck violated state consumer protection laws arising from the sale and marketing of Zetia and Vytorin.

Zetia is a brand-name prescription drug used to lower LDL levels by decreasing cholesterol absorption in the intestinal tract. Vytorin is a combination of Zetia and Zocor, a statin available in generic form.

The suit claims that the combination of drugs was no more effective than the generic version of Zocor in blocking the fatty arterial plaques that can cause heart attack and stroke, as the manufacturers led consumers to believe since 2006.

The companies promoted Zetia heavily, claiming that by adding it to statin treatment, patients could more effectively lower LDL cholesterol which would, in turn, reduce plaque in patients' arteries, according to their advertisements.

But according to the complaint, the companies had prior information that refuted that claim.

To view updates on the case and additional court documents please visit http://www.hbsslaw.com/zetia.htm. You can contact plaintiff's attorneys, Steve Berman or Craig Spiegel at (206) 623-7292 or via e-mail at info@hbsslaw.com.

About Hagens Berman

Hagens Berman, formally Hagens Berman Sobol Shapiro, is based in Seattle with offices in Chicago, Cambridge, Los Angeles, Phoenix and San Francisco. Since 1993, it has developed a nationally recognized practice in class-action and complex litigation. Among recent successes, HBSS has negotiated a $300 million settlement in the DRAM memory antitrust litigation; a $340 million recovery on behalf of Enron employees; a $150 million settlement involving charges of illegally inflated charges for the drug Lupron, and served as co- counsel on the Visa/Mastercard litigation which resulted in a $3 billion settlement, the largest anti-trust settlement to date. HBSS served as counsel in a $850 million Washington Public Power Supply settlement and represented Washington and 12 other states against the tobacco industry that resulted in the largest settlement in history. For a complete listing of HBSS cases, visit http://www.hbsslaw.com.

CONTACTS:

Steve Berman (206) 623-7292

Hagens Berman

Steve@hbsslaw.com

Mark Firmani (206) 443-9357

Firmani + Associates Inc.

Mark@firmani.com


'/>"/>
SOURCE Hagens Berman
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Gunther von Hagens BODY WORLDS Exhibitions Welcome Specimens From Worlds First Living Body Donor for Plastination
2. Gunther Von Hagens BODY WORLDS Exhibitions Mark 25th Million Visitor Milestone
3. Hagens Berman Sobol Shapiro: Nationwide Class Action Certified in Average Wholesale Price Litigation
4. Hagens Berman: Eleven Defendants Settle in Average Wholesale Price Litigation
5. Anatomist Dr. Gunther von Hagens Clarifies: Plastinates Not For Sale
6. CORRECTED: Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough
7. Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia
8. Hagens Berman Sobol Shapiro: Judge Orders Double Damages, Issues Stinging Rebuke in Average Wholesale Price Case
9. Rulings Send Lawsuits Against State Farm, American Family Back to Court, Hagens Berman Sobol Shapiro Announces
10. Jeff Bailet, M.D., Appointed to American Medical Associations Advisory Committee
11. David Pizzo Appointed Blue Cross and Blue Shield of Florida Market President - West Florida
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due to ... a new, often overlooked aspect of head lice: the parasite’s ability to live away from ... common occurrence, but a necessary one in the event that lice have simply gotten out ...
(Date:6/25/2016)... Lewisville, TX (PRWEB) , ... June 25, 2016 , ... ... in the United States, named Dr. Sesan Ogunleye, as the Medical Director of its ... be the facility Medical Director of our new Mesquite location,” said Dr. James M. ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic ... many turn to unhealthy avenues, such as drug or alcohol abuse, as a coping ... released tools for healthy coping following a traumatic event. , Trauma sufferers tend to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... , June 23, 2016 Bracket , a ... its next generation clinical outcomes platform, Bracket eCOA (SM) ... on June 26 – 30, 2016 in Philadelphia ... electronic Clinical Outcome Assessment product of its kind to fully ... Bracket eCOA 6.0 is a flexible platform for ...
Breaking Medicine Technology: